Fluorescence in situ hybridization (FISH): An increasingly demanded tool for biomarker research and personalized medicine

被引：59
作者：
Hu L. [1 ,6 ]
Ru K. [1 ,2 ]
Zhang L. [1 ,3 ]
Huang Y. [4 ]
Zhu X. [1 ,3 ,6 ]
Liu H. [1 ,6 ]
Zetterberg A. [5 ]
Cheng T. [1 ,6 ]
Miao W. [1 ,6 ]
机构：
[1] State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
[2] Department of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
[3] Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
[4] Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin
[5] Department of Oncology-Pathology and Karolinska Cancer Center, Karolinska Institute, Stockholm
[6] Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing Road 288, Tianjin
来源：
Biomarker Research | / 2卷 / 1期
基金：
中国国家自然科学基金;
关键词：
Biomarkers; Fluorescence in situ hybridization (FISH); Genetic aberrations; Hematopoietic malignancies; Personalized medicine; Solid tumors;
D O I：
10.1186/2050-7771-2-3
中图分类号：
学科分类号：
摘要：
Extensive studies of the genetic aberrations related to human diseases conducted over the last two decades have identified recurrent genomic abnormalities as potential driving factors underlying a variety of cancers. Over the time, a series of cutting-edge high-throughput genetic tests, such as microarrays and next-generation sequencing, have been developed and incorporated into routine clinical practice. Although it is a classical low-throughput cytogenetic test, fluorescence in situ hybridization (FISH) does not show signs of fading; on the contrary, it plays an increasingly important role in detecting specific biomarkers in solid and hematologic neoplasms and has therefore become an indispensable part of the rapidly developing field of personalized medicine. In this article, we have summarized the recent advances in FISH application for both de novo discovery and routine detection of chromosomal rearrangements, amplifications, and deletions that are associated with the pathogenesis of various hematopoietic and non-hematopoietic malignancies. In addition, we have reviewed the recent developments in FISH methodology as well. © 2014 Hu et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 102 条
  • [1] Wertheim G.B., Hexner E., Bagg A., Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations, Mol Diagn Ther, 16, 6, pp. 357-369, (2012)
  • [2] Landau D.A., Wu C.J., Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics, Genome Med, 5, 5, (2013)
  • [3] Dietel M., Johrens K., Laffert M., Hummel M., Blaker H., Muller B.M., Lehmann A., Denkert C., Heppner F.L., Koch A., Et al., Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance, Cancer Gene Ther, 20, 4, pp. 211-221, (2013)
  • [4] Boyd C., Boyle D.P., Molecular diagnosis on tissues and cells: how it affects training and will affect practice in the future, Cytopathology, 23, 5, pp. 286-294, (2012)
  • [5] Jiang H., Xue Y., Wang Q., Pan J., Wu Y., Zhang J., Bai S., Wang Q., He G., Sun A., Et al., The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure, Leuk Res, 36, 4, pp. 448-452, (2012)
  • [6] Pathmanathan N., Bilous A.M., HER2 testing in breast cancer: an overview of current techniques and recent developments, Pathology, 44, 7, pp. 587-595, (2012)
  • [7] Kim H.R., Lim S.M., Kim H.J., Hwang S.K., Park J.K., Shin E., Bae M.K., Ou S.H., Wang J., Jewell S.S., Et al., The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma, Ann Oncol, 24, 9, pp. 2364-2370, (2013)
  • [8] Casaluce F., Sgambato A., Maione P., Rossi A., Ferrara C., Napolitano A., Palazzolo G., Ciardiello F., Gridelli C., ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC, Target Oncol, 8, 1, pp. 55-67, (2013)
  • [9] Gandhi L., Janne P.A., Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target, Clin Cancer Res, 18, 14, pp. 3737-3742, (2012)
  • [10] Rowley J.D., Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, Nature, 243, 5405, pp. 290-293, (1973)
12345678910